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Abstract All-trans retinoic acid (ATRA) plays key roles
in neurogenesis mediated by retinoic acid receptors
(RARs). RARs are important targets for the therapeutic
regulation of neurogenesis but effective drug develop-
ment depends on modelling-based strategies to design
high-specificity ligands in combination with good biolog-
ical assays to discriminate between target-specificity and
off-target effects. Using neuronal differentiation as a
model, the aim of this study was to test the hypothesis
that responses across different temporal scales and assay
platforms can be used as comparable measures of retinoid
activity. In biological assays based on cell phenotype or
behaviour, two structurally similar synthetic retinoids,
differing in RAR affinity and specificity, retained their
relative activities across different temporal scales. In con-
trast, assays based on the transcriptional activation of
specific genes in their normal genomic context were less
concordant with biological assays. Gene-induction assays
for retinoid activity as modulators of neurogenesis require
careful interpretation in the light of variation in ligand-
receptor affinity, receptor expression and gene function.
A better characterization of neuronal phenotypes and
their regulation by retinoids is badly needed as a frame-
work for understanding how to regulate neuronal
development.
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Introduction
Retinoic acid (RA) receptor signalling plays key roles in
cell and tissue patterning, neurogenesis and homeostasis,
both directly via nuclear retinoic acid receptors (RARs)
and indirectly by interactions with other ligand-dependent
signalling mechanisms via shared co-factors, receptor
partners and ligand cross-talk [1, 2]. This signalling diver-
sity underlies the potential of RA and related compounds
as important drugs for medicinal use, ranging from cancer
therapeutics to novel treatments for diseases associated
with ageing and neuronal health. In normal cellular and
tissue development, intracellular levels of the main bio-
logically active RA isomer, all-trans RA (ATRA), are
finely regulated by conversion from vitamin A (retinol),
via cellular binding proteins which mediate the transfer of
retinol to retinol dehydrogenases for conversion to ATRA.
The transfer of ATRA to RARs is mediated by cellular
retinoic acid binding proteins (CRABPs) to achieve tran-
scriptional regulation [3, 4] as part of normal cellular ho-
meostasis, and to drive cell and tissue patterning during
embryogenesis and tissue differentiation [1, 4, 5].
RARs are encoded by the transcripts of three separate
genes, RARA (RAR-α), RARB (RAR-β) and RARG
(RAR-γ), and specificity in responses at a cellular level
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are driven by tissue- and stage-specific variation in gene
expression. This is also coupled with variation of splicing
patterns to generate N-terminal variants [6] facilitating
combinatorial interactions with different transcriptional
coregulators [7]. Temporal regulation of gene expression
is facilitated by ATRA degradation mediated by specific
cytochrome P450 enzymes which are themselves regulat-
ed by ATRA [8, 9]. One consequence of this finely tuned
metabolism is that ATRA has a short lifetime when added
to cells or used therapeutically in vivo [10, 11]. Thus,
although the spatial and temporal regulation of ATRA
synthesis and delivery to RARs provides exquisite control
of ATRA-dependent gene expression, this also provides
significant challenges for the development of drugs to
regulate ATRA signalling for clinical benefit. The key
requirements for such drugs will be stability, so that li-
gand concentrations can be maintained in relevant cells
and tissues, and providing sufficient RAR specificity to
target particular processes, tissues or cell types.
There has been considerable progress in designing
retinoid-like molecules which are considerably more sta-
ble than ATRA in intra- and extra-cellular environments
[12]. To be classed as a retinoid, compounds should pro-
duce cellular effects by specific interactions with the li-
gand binding domain of the RARs. Recent modelling
studies have shown that, despite the high degree of se-
quence conservation, there are important differences be-
tween receptor types in the shape of the ligand binding
pocket [13]; this has implications for the design of mod-
ified stable synthetic retinoids for targeting specific bio-
logical processes. Furthermore, it is not just necessary to
ensure good fit of the synthetic retinoid into the ligand
binding domain (LBD) of RARs but also to ensure that
the ligand-LBD complex has sufficient structural integrity
to ensure effective coactivator recruitment for transcrip-
tional regulation [14, 15].
ATRA has an important role in neurogenesis [17],
and we have developed the synthetic retinoids
4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-
ylethynyl)benzoic acid (para-isomer; EC23) and
3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-
ylethynyl)benzoic acid (meta-isomer; EC19) [18] as
tools for studying neurogenesis in vitro (Fig. 1). These
compounds are chemically and biologically more stable
than ATRA; receptor binding and molecular docking
studies show that EC23 binds to all three RARs in a
manner similar to ATRA whereas EC19 has fewer inter-
actions between key residues in the RAR-α and RAR-γ
binding pockets while being a better fit to the larger
binding pocket of RAR-β [13]. However, biological
models are essential for assessing novel retinoids as
potential clinical drugs or experimental tools and to dis-
criminate between RAR-dependent activity and non-
specific or downstream effects. In addition, ATRA may
have distinct concentration-dependent effects in promot-
ing alternative differentiation pathways [16] and for cel-
lular homeostasis [17]. Temporal scale in biological
models is of critical importance, and many assays of
retinoid activity are carried out at long timescales which
may make results hard to reconcile with known RAR
specificity.
The aim of this study was to test the hypothesis that short-
and long-term responses can be used as equivalent measures
of retinoid activity and metabolic stability in assays of syn-
thetic retinoids in neurogenesis models. Neurogenesis and
gene expression at different temporal scales were compared
in TERA2.cl.SP12 pluripotent stem cells and SH-SY5Y neu-
roblastoma cells in response to EC19 and EC23, and their
methyl esters, using ATRA as the positive control. The methyl
esters were included for some assays because although they
show reduced RAR binding activity as a result of the absence
of the key carboxylic acid-arginine residue interaction [13],
esters may be relevant for biological studies if the parent com-
pounds are released by endogenous esterase activity.
Material and Methods
Retinoid Solutions
Stock solutions of synthetic retinoids EC19 and EC23 and
their methyl esters were prepared as reported earlier [18];
ATRAwas from (Sigma-Aldrich, Poole, UK). All compounds
Fig. 1 Chemical structures of
ATRA and the synthetic
analogues, EC23, EC19 and
methyl esters. [9]
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were dissolved in DMSO (Sigma-Aldrich) to 10 mM. Aliquot
stock solutions were stored at −20 °C in the dark.
Cell Culture
Human pluripotent TERA2.cl.SP12 embryonal carcinoma
stem cells were cultured [19], under low-light conditions to
minimize retinoid isomerisation, in Dulbecco’s modification
of Eagle’s medium (DMEM; Sigma-Aldrich) supplemented
with 10% FCS (Gibco), 2 mML-glutamine and 100 units each
of penicillin and streptomycin (Gibco). Cultures were pas-
saged using acid-washed glass beads unless a single-cell sus-
pension was required for counting, in which case, a 0.25%
trypsin/EDTA (Lonza) solution was used. Human SH-SYSY
neuroblastoma cells were cultured in DMEM F12/Ham (1:1)
containing 2 mM L-glutamine, supplemented with 10% FCS
at 37 °C with 5% CO2 in air [20]. Cell suspensions were
obtained by treating adherent cells with 1 ml sterile PBS and
incubation at 37 °C for 3–5 min. Culture media were replaced
every 3–4 days.
Flow Cytometry
Flow cytometry was carried out on live TERA2.cl.SP12
cells, incubated at a density of 0.2 × 106 cells per 25-cm2
flask for 12–24 h before treatment with 10 μM retinoid
for 7 days. Specific cell-surface primary antibodies were
used: SSEA-3 (1:10), (University of Iowa Hybridoma
Bank), TRA-1-60 (1:50), (Abcam) and neural cell marker
A2B5 (1:40), (R&D Systems). Cell suspensions were cen-
trifuged at 1000 rpm and resuspended in wash buffer
(0.1% BSA in PBS) and added to 96-well plate for incu-
bation with the primary antibodies, followed by several
washes and then incubation with FITC-conjugated sec-
ondary antibody IgM (1:128) (Sigma-Aldrich). Labelled
cells were analysed in a GuaveEasyCytePlus System
(Millipore) flow cytometer and thresholds determining
the numbers of positively expressing cells were set
against the negative control antibody, P3X, a generous
gift from Prof. P. Andrews, Sheffield University.
Gene Expression Analysis
Real-time quantitative PCR (qPCR) was carried out on cell ly-
sates immediately after detachment with 0.25% trypsin–EDTA.
Cells were seeded at a density of 1 × 106 cells per 25 cm2 flask
(BD falcon) 12–24 h before retinoid treatment. Commercial
RNA extraction (Qiagen) and reverse transcription (Applied
Biosystems) kits were purchased and procedures used according
to manufacturer instructions. Real-time qPCR was performed
using the TaqMan® Universal PCR master Mix (Life technolo-
gies) and TaqMan® gene expression system (Applied
Biosystems) based on probe sets to the specific genes to be
analysed: RAR-β (Hs00233407_m1), CYP26A1-A1
(Hs00175627_m1), RAR-α (Hs00940448_g1), RAR-γ
(Hs01559234_m1), PAX-6 (Hs01088112_m1), NeuroD1
(Hs01922995_s1). GADPH (Hs02758991_g1) and ACTB
(Hs99999903_m1) were used as internal control genes for
TERA2.cl.SP12 and SH-SY5Y cells, respectively.
Immunocytochemistry
TERA-2.cl.SP12 cells were seeded at 5000 cells per well on
poly-D-lysine (25 μg/ml) coated cover slips 22 × 22 mm, high
precision (170 ± 5 μm) in 6-well plates. At the end of the
experiment, cells were fixed in 4% para-formaldehyde (PFA)
in PBS for 30 min at room temperature and rinsed with PBS.
For intracellular staining, cells were permeabilised with 1%
Triton-X-100 (Sigma) in PBS for 10 min at room temperature.
Non-specific labelling was blocked by incubation for 1 h at
room temperature with 1% goat serum (Sigma) in PBS with
0.2% Tween-20 (Sigma). Primary antibodies were diluted in
blocking solution and incubated with cells for 1 h at room
temperature with a β-III tubulin antibody (TUJ-1) 1:200
(Affymetrix eBioscience) or CK-8 antibody 1:500
(Affymetrix eBioscience). After washing with PBS, cells were
incubated for 1 h in the dark with anti-mouse FITC-conjugat-
ed secondary antibody IgM 1:128 (Sigma) for A2B5 staining
or anti-mouse Alexafluor 488 IgG 1:600 (Invitrogen) for TUJ-
1 and CK-8 staining. Hoechst 33,342 nuclear staining dye
(Molecular Probes) was used at 1:1000 in blocking solution
after the secondary antibody step. Fixed and stained cells were
visualized using a Leica SP5CLSM FLIM FCCS confocal
microscope.
X-gal Bioassay
Sil-15 cells (F9-RARE-lacZ cells) [21] were plated in a 0.1%
gelatin-coated 96-well plate and grown to about 85–90% con-
fluence in DMEM containing 10% foetal calf serum
(Invitrogen/Gibco) and 0.8 mg/ml G418 sulphate (Sigma) for
selection. Cells were washed twice with PBS, fixed with 100 μl
per well of 1% glutaraldehyde for 15 min, washed again twice
with PBS and β-galactosidase activity was visualized with
100 μl of a freshly prepared X-Gal developing solution (5-
bromo-4-chloro-3-indolyl-β-d-galactopyranoside) added to
each well. Colour was read on an Emax microplate reader at
650 nm.
Neurite Outgrowth
SH-SY5Y cells were fixed and stained for TUJ-1 (1:1000;
Sigma) after retinoid treatment for 5 days. For each neurite
outgrowth experiment, 3 cover slips (in 3 wells) were used.
The numbers of neurites were counted and traced for length
measurement using a semi-automatic NeuronJ plugin for
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ImageJ software in each of 10 randomly-selected images for
each cover slip. Average neurite length was calculated by
dividing the total neurite length by the total number of neurites
per image.
Results
Short-Term Responses to Retinoids: SH-SY5Y Cells
Retinoid-Induced Gene Expression
The induction of RAR-β or CYP26A1 transcription is well
established as a marker of retinoid-response [22]; therefore,
the expression of these genes was tested with respect to reti-
noid dose and time of treatment, in addition to investigating
retinoid-induced changes in expression of RAR-α and
RAR-γ. In SH-SY5Y cells, RAR-β expression in response
to 10 μM ATRA or EC23 increased to a maximum at 6 h,
with EC23 showing greater activity. In contrast, EC19 and the
methyl ester showed no, or minimal, activity at 10 μM
(Fig. 2a). With respect to the induction of CYP26A1, only
ATRA had good activity, with a rapid and sustained induction
from 2 to 10 h (Fig. 2c). In dose-response experiments from 1
to 0.001 μM, EC19 and EC23 had similar peak activities for
induction of RAR-β at 0.1 μMwhich exceeded that of ATRA
by about 30% (Fig. 2b). Conversely, for CYP26A1 induction,
although the synthetic retinoids were not inactive, ATRA
showed consistently higher levels of activity over the whole
dose range compared to the synthetic retinoids; indeed, for the
latter, EC19 had greater activity than EC23, except at 1 μM
(Fig. 2d).
As in some other cell types [23], ATRA induced RAR-α
expression, but over a longer timescale than for RAR-β. In
contrast to their induction of RAR-β, the synthetic retinoids
were less effective at inducing RAR-α compared to ATRA;
however, EC23 was at least twice as active as EC19 at the 12-
h timepoint. Substantial induction of RAR-γ was only appar-
ent after 12 h with ATRA and at this time EC19 and EC23
were only marginally more effective than their methyl esters
(Fig. 2e, f).
Neurite Length
SH-SY5Y cells responded morphologically to retinoids
with time-dependent increases in neurite length, with
the greatest differential responses between the retinoids
after 4 days or more [24]. At 0.01 and 10 μM, EC19 had
no neurite-inducing capacity compared with the control
vehicle (DMSO), unlike EC23, which had similar activ-
ity to ATRA at 0.01 μM (Fig. 2j); however, in contrast
to ATRA which gave a dose-dependent increase in
neurite length, the response to EC23 appeared saturated
at 0.01 μM. Neurite extension is a lower-resolution tech-
nique over a more-extended timescale than the gene-
expression assays, and there were clear differences be-
tween these assays in the relative activities of all reti-
noids at 10 μM (Fig. 2j).
X-Gal Reporter Bioassay Analysis
The relative transcriptional potency of the retinoids was also
tested on Sil-15 reporter cells, which are F9 murine teratocar-
cinoma cells stably transfected with a LacZ gene under the
control of a RA response element (RARE) promoter [21]. β-
Galactosidase activity in these cells was assayed over retinoid
concentration ranges of 10−6 M to 10−14 M over 24 h. EC23
was effective over the entire range, giving a 50% response
between 10−11 to 10−12 M, compared to the 50% response of
ATRA at 5 × 10−10 M. In contrast, EC19 showed very little
activity (Fig. 2k).
Longer-Term Responses to Retinoids: TERA-2. cl.SP12
Cells
Cell Differentiation Markers
ATRA-induced differentiation of TERA2.cl.SP12 cells is
characterized by the downregulation of the glycolipid an-
tigen SSEA3 and the keratan sulphate-related antigen
TRA-1-60, and the upregulation of the c-series ganglio-
side-specific antigen A2B5, characteristic of neuronal and
glial cells [19]. TERA2.cl.SP12 cells were treated with
10 μM of each retinoid for 7 days and analysed for the
expression of SSEA3, TRA-1-60 and A2B5 by flow cy-
tometry. Control cultures, untreated or treated with the
DMSO vehicle alone, showed high expression levels of
SSEA-3 and TRA-1-60 with 60–70% of cells expressing
these markers, but less than 20% of these cells expressing
the neuronal differentiation marker A2B5 (Fig. 3a, b).
After treatment with either 10 μM ATRA or EC23 for
7 days, there was a significant reduction in expression
of SSEA-3 (20% of cells) and TRA-1-60 (50% of cells)
and an induction of expression of A2B5, indicating a shift
from a pluripotent state towards neuronal differentiation
which was particularly marked with EC23; conversely,
EC19 was less effective (Fig. 3a, b). The methyl ester of
EC23 was less active than the parent compound, while the
EC19 methyl ester was as active, or slightly more so, than
EC19 (Fig. 3b).
Cel l morphology and phenotypic fate wi th in
TERA2.cl.SP12 cell cultures were assessed by immuno-
cytochemistry for neuronal markers (cell-surface A2B5;
cytoplasmic βIII-tubulin, TUJ-1 antibody), and the epi-
thelial marker cytokeratin 8 (CK-8). Control cultures
(DMSO vehicle) showed low expression of all markers.
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After exposure to ATRA or EC23 for 7 days, expression
of the neuronal markers substantially increased, in con-
trast to CK-8. After 14 and 21 days, βIII-tubulin
expression increased further with the formation of more ma-
ture, differentiated neuronal cells where staining was localized
to the cytoplasm and neuronal processes. In contrast, EC19
a c e
b d f
g h i j
k
Fig. 2 Short-term assay of retinoid properties in SH-SY5Y cells and Sil-
15 reporter cells. a–f Real-time quantitative PCR (qPCR) analysis of
mRNA expression for RAR-β (a time course, b dose-response),
CYP26A1 (c time course, d dose-response), RAR-α (e time course)
and RAR-γ (f time course) in SH-SY5Y cells treated with (left to right)
ATRA, EC19, EC23 and methyl ester analogues. Dose-response experi-
ments were performed with retinoid concentrations of 1, 0.1, 0.01 and
0.001μM for 8 h, and time course experiments with 10μMfor up to 12 h.
Quantification of target mRNA was relative to SH-SY5Y cells cultured
with DMSO vehicle for the relevant time period and normalized to the
internal reference gene (ACTB). Data represent mean ± SEM, n = 3.
Neurite outgrowth by SH-SY5Y cells in response to control vehicle or
EC19 or EC23 (10 μM each) is shown in the images (g–i), stained with
the anti-beta III tubulin antibody TUJ-1 (scale bar 50 μm) (g control, h
EC19, i EC23) and (j) bar graph for mean neurite length (pixels ± SEM,
n = 3). There was a significant induction of neurite outgrowth in response
to EC23 (ANOVA, P < 0.001) but not EC19, and no effect of dose at the
concentrations used. The response by Sil-15 reporter cells to increasing
concentrations of ATRA, EC19 or EC23 is shown in k where grey
shading along the fitted curves defines the 95% confidence limits for
the EC23 and EC19 data
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did not induce any substantial increase in expression of
A2B5 or βIII-tubulin after 7 days, with low levels of
βIII-tubulin-positive cells even after 21 days. However,
the expression of CK-8 increased in EC19-treated cultures
after 21 days, suggesting differentiation towards an epithe-
lial phenotype (Fig. 3c).
Fig. 3 Longer-term assay of retinoid responses using the cell
differentiation model of TERA2.cl.SP12 stem cells treated with 10 μM
ATRA, EC19, EC23 or their methyl esters after 7 days. Control
TERA2.cl.SP12 cultures were treated with 1% DMSO vehicle. a Flow
cytometry analysis showing 2D plots of gated cells expressing SSEA-3
and A2B5 after retinoid treatment. b Histograms of percentage positive
cells for the stem cell-surface markers SSEA-3, TRA-1-60 and the early
stage neuronal marker A2B5. Results are presented as ±SEM, n = 3; P
values for comaprisons with control are: *P < 0.05; **P < 0.01;
***P < 0.001. c Photomicrographs of TERA2.cl.SP12 cells stained for
the neuronal (A2B5 and TUJ-1) and epithelial (CK-8) proteins after ex-
posure to 10 μMATRA, EC19 or EC23 for 1, 2 and 3 weeks. Scale bar,
25 μm
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Expression of Neuronal Lineage Marker Transcripts
The neuronal markers NeuroD1 and PAX-6 are predominantly
expressed in the nervous system, particularly later in develop-
ment [25, 26]. NeuroD1 was upregulated in TERA2.cl.SP12
cells showing a linear time-dependent increase in response to
10 μM ATRA or EC23; EC19 and the methyl esters of both
synthetic retinoids had much lower activities (Fig. 4a). PAX6
was substantially upregulated only after 7 days of treatment
and EC23 was 10 times more effective than ATRAwith very
little activity shown by EC19 (Fig. 4b).
Discussion
With respect to the parent compounds, there were generally
concordant responses, summarized by rank in Table 1, be-
tween long-term and short-term biological response assays
(differentiation, neurite extension, reporter assays) where both
EC23 and EC19 maintained their relative activities over dif-
ferent temporal scales. The methyl esters of EC23 and EC19
usually had low, or intermediate, activity. Although structural
studies and ligand binding/activity assays suggest that these
methyl esters may have direct activity as RAR ligands in their
own right [13], esterase activity [27] releasing the free parent
carboxylic acids may also contribute to biological activity. In
contrast to biological response assays, assays of specific gene
transcripts, whether as markers of neural differentiation status
as with the NeuroD1 and PAX6 transcripts, or of short-term
responses to retinoids such as the induction of expression of
RARs or CYP26A1, were not directly comparable with the
broader biological responses. This was particularly true for
EC19 which, as predicted from structural studies, had activity
in some gene-response assays but low activity in biological
response assays. These results highlight two key factors in
responses to retinoids: the dynamic mechanisms of individual
gene regulation by retinoids and the retinoid mechanisms
directing biological responses.
Individual retinoid-responsive genes, RAR-β and
CYP26A1, responded differently with respect to temporal
characteristics of activation and relative activities of the dif-
ferent retinoids at different doses. For CYP26A1 induction,
ATRA showed the highest activity; unexpectedly, EC19 had
greater CYP26A1 induction activity than EC23 at lower
doses, but, in contrast to ATRA, both were ineffective at
10 μM. For RAR-β induction, both synthetic retinoids were
equally effective at low doses and with greater activity than
ATRA, whereas at higher doses, EC23 had the greatest activ-
ity with EC19 having much lower activity compared to
ATRA.
Variability in behaviour between different short-term gene-
response assays can be due to a combination of factors, par-
ticularly RARE context, RAR expression and specificity [28],
and retinoid metabolism. Recent structural modelling studies
have shown that the RAR-β LBD is better than other RAR
LBDs at accommodating the geometrically differently
substituted ring of EC19 with the carboxylic acid group in
the meta-position [13]; the good activity of EC19 with respect
to the induction of RAR-β suggests that this induction may be
driven primarily by constitutive expression of RAR-β in these
cells. This is in agreement with other studies [29] implying a
dependence of RAR-β induction on RAR-β itself in SH-
SY5Y cells. In the Sil-15 reporter cells, β-galactosidase activ-
ity is driven by an RAR-βRARE construct; the low activity of
EC19 in this system compared to the induction of RAR-β
transcripts in SH-SY5Y cells may result from differences in
basal RAR-β expression between the two cell types, as this
appears to be relatively lower in Sil-15 parental cells [30]
compared to SH-SY5Y cells.
The genomic context of RAREs which drive marker genes,
the availability of promoter-specific coregulators and retinoid-
specific co-regulator interactions are also important consider-
ations for the interpretation of retinoid activity assays.
Transcriptional activation by ligand-bound RARs requires
ligand-dependent conformational changes in the receptor to
Fig. 4 NeuroD1 (a) and PAX6 (b) gene expression in TERA2.cl.SP12
stem cells treated with 10μMofATRA, EC19, EC23 or their methyl ester
analogues for 3, 5 and 7 days. Quantification is relative to
TERA2.cl.SP12 cells cultured with 0.1% DMSO vehicle for 7 days and
all data (mean ± SEM, n = 3) were normalized to the internal reference
gene (GADPH)
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facilitate coactivator recruitment [31]; these may vary inde-
pendently of ligand-LBD affinity such that retinoids with
equivalent affinity for RAR LBDs may differ in their ability
to facilitate coactivator recruitment [13]. Gene-specific induc-
tion mechanisms are also evidenced by the relatively poor
activity of the synthetic retinoids on CYP26A1 induction
compared to ATRA; in this respect, coregulators may be crit-
ical in driving specificity because CYP26A1 needs to respond
to ATRA specifically to regulate ATRA levels. It is also pos-
sible that RARs may bind to other endogenous ligands, such
as ATRA metabolites [32], and these should also be consid-
ered as potential drivers of CYP26A1 induction. Clearly, sin-
gle gene assays have limited use as surrogate markers of the
biological properties of synthetic retinoids.
Overall, these results imply that the assay based on Sil-15
cells, or on cells with an equivalent RARE-driven reporter, is a
good short-term assay as it gave comparable results to longer-
term, and more time-consuming, assays of biological re-
sponses for assessing the potency of novel synthetic retinoids.
In the long-term assays, the relative induction of neurogenesis
by different retinoids, as indicated by downregulation of
markers of pluripotency and the upregulation of neuronal lin-
eage markers, was comparable to the induction of RAR-α
messenger RNA (mRNA) at a shorter timescale. This may
imply a role for RAR-α as an initial step in the induction of
neurogenesis, either via a transcriptional or non-
transcriptional mechanism [33], and is supported by the dif-
ferent relative activities of EC19 in the induction of RAR-β
and neurite extension in SH-SY5Y cells.
These studies also stress the importance of careful marker
selection for retinoid assays. The transcription factor PAX6 is
reported to promote neurogenesis [34], but in TERA2.cl.SP12
cells, PAX6 was upregulated substantially more in response to
EC23 than ATRA, compared to the E-box transcription factor
NeuroD1, implying that neuronal phenotypes may be driven
to different extents by different retinoids. If neurogenesis is
also regulated by the products of ATRA catabolism [9], then
EC23 or comparable synthetic retinoids might have biological
effects on neurogenesis that are qualitatively different to
ATRA because of greater metabolic stability. As has been
shown previously, EC19 does not induce neurogenesis of
TERA2.cl.SP12 cells but induces an epithelial phenotype
[18]; whether this is an RAR-driven process, perhaps mediat-
ed by different RAR specificities of EC19, is not clear.
However, this could also result from non-specific effects such
as arachidonic acid signalling as a consequence of high levels
of lipophilic compounds impacting upon membrane lipids
[20].
In summary, specific gene-induction assays for novel reti-
noids require careful interpretation as measures for their po-
tential as modulators of neurogenesis. Changes in cell pheno-
type or behaviour over different temporal scales may, superfi-
cially, be simpler to interpret; nevertheless, a much better un-
derstanding and characterization of neuronal phenotypes and
their regulation is badly needed to provide a framework for
understanding the wider value of synthetic retinoids for regu-
lating neuronal development.
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